Recruiting Heart Attack Studies in Mobile
A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome
The purpose of this study is to evaluate that milvexian is superior to placebo, in addition to standard-of-care, in reducing the risk of major adverse cardiovascular event (MACE) (the composite of car...
ARTEMIS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With a Heart Attack
The research study is being done to see if ziltivekimab can be used to treat people who were admitted to hospital because of a heart attack. Ziltivekimab might reduce development of heart disease, the...
Effect of Dalcetrapib on CV Risk in a Genetically Defined Population With a Recent ACS
This is a placebo-controlled, randomized, double-blind, parallel group, phase 3 multicenter study in subjects recently hospitalized for ACS and with the appropriate genetic profile. Subjects will prov...
A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)
The goal of this study is to evaluate nemtabrutinib compared with investigator's choice of ibrutinib or acalabrutinib in participants with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma...
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
This study aims to use clinical and biological characteristics of acute leukemias to screen for patient eligibility for available pediatric leukemia sub-trials. Testing bone marrow and blood from pati...
A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
This phase II trial studies the effect of nivolumab in combination with blinatumomab compared to blinatumomab alone in treating patients with B-cell acute lymphoblastic leukemia (B-ALL) that has come ...
A Study of Lower Radiotherapy Dose to Treat Children With CNS Germinoma
This phase II trial studies how well lower dose radiotherapy after chemotherapy (Carboplatin \& Etoposide) works in treating children with central nervous system (CNS) germinomas. Radiation therapy us...
A Study in Patients With Mixed Dyslipidemia
A Phase 2 in Patients With Mixed Dyslipidemia...
About Heart Attack Clinical Trials in Mobile
A heart attack (myocardial infarction) occurs when blood flow to part of the heart muscle is blocked, usually by a blood clot. It is a medical emergency requiring immediate treatment. Long-term management includes medications, lifestyle changes, and cardiac rehabilitation.
There are currently 8 heart attack clinical trials recruiting participants in Mobile, AL. These studies are seeking a combined 30,993 participants. Research is being sponsored by Janssen Research & Development, LLC, Novo Nordisk A/S, DalCor Pharmaceuticals and 5 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.
Heart Attack Clinical Trials in Mobile — FAQ
Are there heart attack clinical trials in Mobile?
Yes, there are 8 heart attack clinical trials currently recruiting in Mobile, AL. Browse the studies on this page to find one that fits.
How do I join a clinical trial in Mobile?
Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Mobile research site will contact you about next steps.
Are clinical trials in Mobile free?
Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Mobile studies also compensate for your time and travel.
What heart attack treatments are being tested?
The 8 active trials in Mobile are testing new therapies including novel drugs, biologics, and treatment approaches for heart attack.
Data updated March 2, 2026 from ClinicalTrials.gov